在动物模型中Olaparib和Regorafenib之间的药理动力相互作用
Danuta Szkutnik-Fiedler1, Agnieszka Karbownik1, Filip Otto1
1Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, 60-806 Poznań, Poland.
Pharmaceutics
|January 8, 2025
概括
当Olaparib (OLA) 和regorafenib (REG) 同时使用时显著相互作用,在老鼠中改变彼此的药理动力学. 这项临床前研究强调了OLA和REG一起使用时对药物安全的潜在临床相关性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 药物相互作用 药物相互作用
背景情况:
- 奥拉巴里布 (OLA) 和雷戈拉费尼布 (REG) 通过CYP3A4代谢,并与P-糖蛋白和BCRP载体相互作用.
- 同时使用OLA和REG可能会导致显著的药物相互作用.
- 了解载体和酶的影响对于评估药物的有效性和安全性至关重要.
研究的目的:
- 评估OLA和REG及其活性代谢物之间的药理学相互作用.
- 在临床前的老鼠模型中评估同时使用的双边效应.
主要方法:
- 雄性Wistar大鼠 (n=24) 被分为三个组:REG+OLA,单独的REG和单独的OLA.
- 超高性能液态染色学-并联质谱学 (UPLC-MS/MS) 用于量化OLA,REG和代谢物M-2和M-5.
- 非分区分析确定了药物动力学参数.
主要成果:
- OLA显著增加了REG暴露 (AUC0-∞增加了3.38倍),并减少了其消除 (k_el,Cl/F).
- REG显著增加了OLA暴露 (AUC0-∞增加了3.4倍),并降低了其清除率 (Cl/F).
- 活性代谢物M-2和M-5的度和代谢物/原始物比率显著增加.
结论:
- 同时使用OLA和REG会在老鼠中产生显著的药物动力学相互作用.
- 这两种药物都是中度抑制剂,REG和OLA的AUC比率约为3.4.
- 结果表明潜在的临床相关性,并保证在人体研究中进一步调查.
相关概念视频
Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...


